{"entity":{"id":"prkcq","kind":"target","name":"PRKCQ","aka":["protein kinase C theta","Protein kinase C theta type"],"tldr":"PRKCQ (Protein kinase C theta type) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Systemic mastocytosis and 1 more.","summary":"Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that mediates non-redundant functions in T-cell receptor (TCR) signalling, including T-cells activation, proliferation, differentiation and survival, by mediating activation of multiple transcription factors such as NF-kappa-B, JUN, NFATC1 and NFATC2. In TCR-CD3/CD28-co-stimulated T-cells, is required for the activation of NF-kappa-B and JUN, which in turn are essential for IL2 production, and participates in the calcium-dependent NFATC1 and NFATC2 transactivation. Mediates the activation of the canonical NF-kappa-B pathway (NFKB1) by direct phosphorylation of CARD11 on several serine residues, inducing CARD11 association with lipid rafts and recruitment of the BCL10-MALT1 complex, which then activates IKK complex, resulting in nuclear translocation and activation of NFKB1.\n\nOpen Targets scores its association with cancer at 0.61 (direct and indirect evidence; datatypes literature 0.93, animal model 0.80, genetic association 0.17, clinical 0.92).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:9410","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9410"},{"label":"UniProt Q04759","url":"https://www.uniprot.org/uniprotkb/Q04759/entry"},{"label":"NCBI Gene 5588","url":"https://www.ncbi.nlm.nih.gov/gene/5588"},{"label":"Ensembl ENSG00000065675","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000065675"}],"tags":["cancer-genes-wave"],"related":["open-targets"],"cancers":["leukaemia","myeloproliferative-neoplasms","systemic-mastocytosis","aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.94. Evidence tier \"approved-drug\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"PRKCQ","role":["drug-target"],"evidenceTier":"approved-drug","sources":[{"label":"HGNC HGNC:9410","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9410","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt Q04759","url":"https://www.uniprot.org/uniprotkb/Q04759/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"Open Targets ENSG00000065675","url":"https://platform.opentargets.org/target/ENSG00000065675/associations","note":"association with cancer (MONDO_0004992) 0.61; per-cancer scores at or above 0.5: acute myeloid leukaemia 0.56, myeloproliferative neoplasm 0.56, systemic mastocytosis 0.54, leukaemia 0.57 (GraphQL API, CC0)"}],"distribution":"few-types","specificityNote":"Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA group enriched, which says where the protein sits but not whether the tumour differs from normal tissue. HPA PRKCQ: RNA group enriched (lymphoid tissue 31 nTPM, skeletal muscle 115 nTPM, tongue 105 nTPM); blood lineage group enriched (NK-cells 13 nTPM, T-cells 40 nTPM); no normal tissue stained high. Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Leukaemia, Myeloid neoplasms); Open Targets associates it with 1 specific cancer type at or above 0.5 (acute myeloid leukemia). (No rule of scripts/fetch-target-specificity.ts fired.)","specificitySources":[{"label":"Human Protein Atlas PRKCQ tissue","url":"https://www.proteinatlas.org/ENSG00000065675-PRKCQ/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000065675 associations","url":"https://platform.opentargets.org/target/ENSG00000065675/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:9410","ensembl":"ENSG00000065675","uniprot":"Q04759","entrez":"5588","firstDescribed":1993,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Chang J.D. et al, J. Biol. Chem, 1993, \"Molecular cloning and expression of a cDNA encoding a novel isoenzyme of protein kinase C (nPKC). A new member of the nPKC family expressed in skeletal muscle, megakaryoblastic cells, and platelets\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/7686153/","biology":"Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that mediates non-redundant functions in T-cell receptor (TCR) signalling, including T-cells activation, proliferation, differentiation and survival, by mediating activation of multiple transcription factors such as NF-kappa-B, JUN, NFATC1 and NFATC2. In TCR-CD3/CD28-co-stimulated T-cells, is required for the activation of NF-kappa-B and JUN, which in turn are essential for IL2 production, and participates in the calcium-dependent NFATC1 and NFATC2 transactivation. Mediates the activation of the canonical NF-kappa-B pathway (NFKB1) by direct phosphorylation of CARD11 on several serine residues, inducing CARD11 association with lipid rafts and recruitment of the BCL10-MALT1 complex, which then activates IKK complex, resulting in nuclear translocation and activation of NFKB1. May also play an indirect role in activation of the non-canonical NF-kappa-B (NFKB2) pathway. In the signalling pathway leading to JUN activation, acts by phosphorylating the mediator STK39/SPAK and may not act through MAP kinases signalling. Plays a critical role in TCR/CD28-induced NFATC1 and NFATC2 transactivation by participating in the regulation of reduced inositol 1,4,5-trisphosphate generation and intracellular calcium mobilisation. Location: Cytoplasm; Cell membrane (UniProt). Locus 10p15.1 (HGNC).","whereFound":["Leukaemia: Open Targets association 0.57 with leukaemia (MONDO_0005059)","Myeloproliferative neoplasms: Open Targets association 0.56 with myeloproliferative neoplasm (MONDO_0020076)","Systemic mastocytosis: Open Targets association 0.54 with systemic mastocytosis (MONDO_0016586)","Acute myeloid leukaemia: Open Targets association 0.56 with acute myeloid leukaemia (MONDO_0018874)"],"targetClass":"kinase","prevalence":[]},"route":"/targets/prkcq/","neighbours":{"collection":[{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/"},{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"},{"id":"systemic-mastocytosis","kind":"cancer","name":"Systemic mastocytosis","route":"/cancers/systemic-mastocytosis/"}]}}